Screener
Ultragenyx Pharmaceutical RARE Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -73.6%+9.2pp | -83.7%+3.3pp | -79.5%+16.2pp | -86.3%+16.2pp | -82.8%+31.2pp | |
| Net margin | -81.7%+5.6pp | -90.9%+2.2pp | -85.4%+16.2pp | -91.9%+15.1pp | -87.3%+34.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.5×+0.1× | 0.4×+0.1× | 0.5×+0.1× | 0.4×+0.1× | |
| Liquidity | ||||||
| Current ratio | 1.7×-0.7× | 2×-0.4× | 2.5×+0.1× | 1.9×-0.9× | 2.5×-1.1× | |
| Per Share | ||||||
| Book value per share | -$2.86-286% | -$2.35-257% | -$0.81-129% | $0.09-97.5% | $1.53-69.3% | |
| Valuation | ||||||
| Market capitalization | $2.55B-5.8% | $2.06B-39.4% | $2.22B-42.9% | $2.9B-39.7% | $3.51B+1.4% | |
| Price / sales | 3.6×-0.9× | 3.1×-2.7× | 3.3×-3.6× | 4.6×-4.6× | 5.8×-1.4× |
FAQ
- What are Ultragenyx Pharmaceutical's profit margins?
- Ultragenyx Pharmaceutical (RARE) runs a 97.2% gross margin and a -73.6% operating margin, with a -81.7% net margin.
- Where do Ultragenyx Pharmaceutical's ratios come from?
- Every ratio is computed from Ultragenyx Pharmaceutical's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
